Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Gastrointestinal disorders – page 78

  • 1 123 clinical trials
  • 490 recruiting
  • 469 conditions
  • 28 countries

Conditions in this area

469 conditions with trials, the busiest first

Colitis ulcerative120Colorectal cancer metastatic105Crohn's disease94Colorectal cancer89Pancreatic carcinoma57Gastric cancer55Oesophageal adenocarcinoma48Systemic scleroderma39Pancreatic carcinoma metastatic35Adenocarcinoma pancreas34Rectal cancer33Oesophageal carcinoma32Sjogren's syndrome29Adenocarcinoma gastric28Ovarian cancer27Non-small cell lung cancer26Breast cancer25Colon cancer25Gastrooesophageal cancer25Cystic fibrosis24Hepatocellular carcinoma18Fallopian tube cancer17Endometrial cancer16Gastroenteropancreatic neuroendocrine tumour disease16+445

Clinical trials in Gastrointestinal disorders

1 123 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 123 clinical trials

Colorectal cancer metastatic

Not recruiting

Study Comparing Nivolumab, Nivolumab with Ipilimumab, or Chemotherapy for Patients with Metastatic Colorectal Cancer with High Microsatellite Instability

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Gastrooesophageal reflux disease

Not recruiting

Study on the Safety and Effectiveness of Dexlansoprazole for Treating Nonerosive GERD in Children Aged 2 to 11 Years

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Dexlansoprazole
  • Sponsor:Takeda Development Center Americas Inc.

Erosive oesophagitis

Not recruiting

Study on Dexlansoprazole for Treating and Maintaining Healing of Erosive Esophagitis in Children Aged 2 to 11 Years

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Dexlansoprazole
  • Sponsor:Takeda Development Center Americas Inc.

Oesophageal squamous cell carcinoma

Not recruiting

Study of Durvalumab with Chemoradiation Therapy for Patients with Locally Advanced, Unresectable Esophageal Squamous Cell Carcinoma

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:AstraZeneca AB

Oesophageal carcinoma+1

Not recruiting

Study on Tocilizumab for Patients with Esophageal Cancer to Improve Chemoradiotherapy Outcomes

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Tocilizumab
  • Sponsor:Amsterdam UMC Stichting

Erosive oesophagitis

Not recruiting

Study on Esomeprazole Magnesium for Maintaining Healing of Erosive Esophagitis in Children Aged 1 to 11 Years

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Esomeprazole Magnesium
  • Sponsor:AstraZeneca AB

Colitis ulcerative+2

Not recruiting

Study on Subcutaneous Infliximab for Patients with Ulcerative Colitis, Crohn's Disease, or Unclassified Inflammatory Bowel Disease

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Infliximab
  • Sponsor:Belgian IBD Research and Development

Colorectal cancer

Not recruiting

Study for Patients with Metastatic Colorectal Cancer with BRAF V600E Mutation Using Encorafenib, Cetuximab, and Chemotherapy Combination

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Pfizer Inc.

Basal cell naevus syndrome

Not recruiting

Study on Patidegib Gel for Reducing Basal Cell Carcinomas in Adults with Gorlin Syndrome

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Patidegib Hydrochloride Isopropanolate
  • Sponsor:Sol-Gel Technologies Ltd.

Malignant peritoneal neoplasm+3

Not recruiting

Study of Farletuzumab Ecteribulin vs. Chemotherapy for Women with Platinum-resistant High-grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Paclitaxel
  • Sponsor:Bristol Myers Squibb International Corporation

Colon cancer stage II+1

Not recruiting

Study on Adjuvant Therapy with Capecitabine for Stage II Colon and Rectal Cancer Patients with Positive ctDNA After Tumor Removal

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Technische Universitaet Dresden

Colorectal cancer metastatic

Not recruiting

Study Comparing Sacituzumab Govitecan with Standard Treatment for Patients with Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Substances studied in this area

The therapies tested most often in Gastrointestinal disorders trials.

Fluorouracil205 clinical trialsOxaliplatin195 clinical trialsCapecitabine108 clinical trialsFolinic Acid83 clinical trialsBevacizumab72 clinical trialsCalcium Folinate67 clinical trialsPembrolizumab57 clinical trialsIrinotecan Hydrochloride Trihydrate52 clinical trialsNivolumab48 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.